Acotiamide

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Acotiamide
Acotiamide.svg
Clinical data
Trade namesAcofide (JP)
Routes of
administration
By mouth (tablets)
ATC code
  • None
Legal status
Legal status
  • US: Currently not FDA approved
  • Rx-only (JP)
Pharmacokinetic data
Protein binding84.21–85.95%
MetabolismUGT1A8 and 1A9 (major)
Elimination half-life10.9–21.7 hours
ExcretionFeces (92.7%), urine (5.3%)[1]
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC21H30N4O5S
Molar mass450.55 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Acotiamide (brand name Acofide, codenamed YM-443 and Z-338) is a drug manufactured and approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.[2] It acts as an acetylcholinesterase inhibitor. It is pending approval in the United States; ten clinical trials have been successfully completed.

References[edit]

  1. ^ "Acofide (acotiamide hydrochloride hydrate) Tablets Review Report" (PDF). Retrieved 29 December 2016.
  2. ^ Matsueda, K; Hongo, M; Tack, J; Aoki, H; Saito, Y; Kato, H (June 2010). "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients withfunctional dyspepsia – 100 mg t.i.d. is an optimal dosage". Neurogastroenterology & Motility. 22 (6): 618-e173. doi:10.1111/j.1365-2982.2009.01449.x. PMID 20059698.